Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05447286 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT05447286 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 9 participants.
The verdict
NCT05447286, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals with current recreational use.
Interventions
- DRUG Placebo
- DRUG Oxycodone
- DRUG NYX-783
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2023-05-15 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05447286
The ClinicalTrials.gov registry entry for NCT05447286 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05447286 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05447286 about?
NCT05447286 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study". This study proposes to examine the safety, tolerability, and pharmacokinetics (PK) of NYX-783 50 mg and 150 mg versus Placebo (PBO) in combination with acute Oxycodone 15 mg and 30 mg in an inpatient randomized, cross-over study in non-treatment seeking non-dependent, opioid experienced individuals ...
What is the current status of trial NCT05447286?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2023-05-15. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT05447286?
The interventions under investigation include: Placebo (DRUG), Oxycodone (DRUG), NYX-783 (DRUG).
Who is sponsoring clinical trial NCT05447286?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.